| Identification | Back Directory | [Name]
IP7E | [CAS]
500164-74-9 | [Synonyms]
IP7E
isoxazolo-pyridinone 7e
inhibit,IP7e,Inhibitor,orally,Nurr1,NF-kB,brain-penetrant
6-[4-[(2-Methoxyethoxy)methyl]phenyl]-5-methyl-3-phenyl-isoxazolo[4,5-c]pyridin-4(5H)-one
Isoxazolo[4,5-c]pyridin-4(5H)-one, 6-[4-[(2-methoxyethoxy)methyl]phenyl]-5-methyl-3-phenyl-
6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one | [Molecular Formula]
C23H22N2O4 | [MDL Number]
MFCD30182349 | [MOL File]
500164-74-9.mol | [Molecular Weight]
390.43 |
| Hazard Information | Back Directory | [Uses]
IP7e is an activator of Nurr1 signaling pathway. | [Biological Activity]
Cell permeable: yes''Primary Target
Nurr1/NR4A2 | [in vivo]
IP7e (Isoxazolo-pyridinone 7e; 10 mg/kg; oral gavage; twice a day) preventive treatment reduces the incidence and the severity of a MS murine model, i.e. experimental autoimmune encephalomyelitis (EAE). IP7e attenuates inflammation and neurodegeneration in spinal cords of EAE mice by an NF-kB pathway-dependent process[2]. | Animal Model: | Female C57BL/6J mice (6-8 week-old) with experimental autoimmune encephalomyelitis (EAE)[2].
| | Dosage: | 10 mg/kg | | Administration: | Oral gavage; twice a day; preventive administration (before the disease onset) from 7 to 23 d.p.i. and therapeutic (after the disease onset) from 21 to 36 d.p.i. | | Result: | Preventive administration delayed the onset and reduces the incidence and severity of EAE, and decreased neuroinflammatory and histopathological alterations in the spinal cord of treated EAE mice. On the contrary, the course of EAE was not influenced by the therapeutic administration. |
| [IC 50]
Nurr1/NR4A2 | [storage]
Store at -20°C |
|
|